Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dysregulated Tyrosine Kinase Signaling in Leukemia

This study has been completed.
Information provided by:
University of New Mexico Identifier:
First received: January 11, 2006
Last updated: January 6, 2010
Last verified: April 2008

Dysregulated Tyrosine Kinase Signaling in Leukemia


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dysregulated Tyrosine Kinase Signaling in Leukemia

Resource links provided by NLM:

Further study details as provided by University of New Mexico:

Biospecimen Retention:   Samples With DNA

blood bone marrow

Enrollment: 30
Study Start Date: May 2002
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

people with leukemia


Inclusion Criteria:

  • Patients must have newly diagnosed or relapsed leukemia.
  • Patients must sign an informed consent.
  • Patients will not be excluded if they are receiving chemotherapy.
  • Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
  • Patients must be => 18 years of age.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277056

United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Principal Investigator: Ian Rabinowitz, MD University of New Mexico
  More Information

No publications provided

Responsible Party: Ian Rabinowitz, MD, University of New Mexico CRTC Identifier: NCT00277056     History of Changes
Other Study ID Numbers: 1602C
Study First Received: January 11, 2006
Last Updated: January 6, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:

Additional relevant MeSH terms:
Neoplasms by Histologic Type processed this record on November 25, 2014